| scholarly article | Q13442814 |
| P356 | DOI | 10.1128/AAC.46.1.171-177.2002 |
| P8608 | Fatcat ID | release_xrzonuneyzb7bak3vhjdendcdi |
| P932 | PMC publication ID | 126986 |
| P698 | PubMed publication ID | 11751129 |
| P2093 | author name string | J M Entenza | |
| M P Glauser | |||
| P Moreillon | |||
| P Hohl | |||
| I Heinze-Krauss | |||
| P2860 | cites work | In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 |
| Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance | Q28361569 | ||
| Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus | Q35124432 | ||
| Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats | Q35823261 | ||
| Natural history of aortic valve endocarditis in rats | Q36328909 | ||
| Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci | Q36752622 | ||
| Beta-Lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci | Q36753343 | ||
| In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. | Q39779171 | ||
| Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins | Q40431109 | ||
| Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography | Q41265449 | ||
| Importance of beta-lactamase inactivation in treatment of experimental endocarditis caused by Staphylococcus aureus | Q41611983 | ||
| Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. | Q41696128 | ||
| Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits | Q42278485 | ||
| Antibiotic treatment of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis | Q42283256 | ||
| The impact of penicillinase on cefamandole treatment and prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus aureus | Q42545796 | ||
| New Gram-positive agents in nosocomial infection. | Q53973330 | ||
| The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. | Q54105049 | ||
| Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. | Q55067143 | ||
| Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus | Q68198941 | ||
| First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital | Q74716023 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| P304 | page(s) | 171-177 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis | |
| P478 | volume | 46 |
| Q36233502 | Anti-MRSA agents: under investigation, in the exploratory phase and clinically available |
| Q36763997 | Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy |
| Q35588850 | Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review |
| Q36283731 | Antibiotic resistance in Staphylococcus aureus and its relevance in therapy |
| Q36968150 | Antimicrobial therapy of Staphylococcus aureus bloodstream infection |
| Q41847350 | Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin |
| Q44655200 | Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinone-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci |
| Q34624359 | Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae |
| Q36396146 | Ceftobiprole efficacy in vitro against Panton-Valentine leukocidin production and in vivo against community-associated methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits |
| Q42027484 | Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus |
| Q43993247 | Ceftobiprole medocaril is an effective treatment against methicillin-resistant Staphylococcus aureus (MRSA) mediastinitis in a rat model |
| Q34433342 | Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia |
| Q37762092 | Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus |
| Q37519733 | Ceftobiprole: a new broad spectrum cephalosporin |
| Q37593094 | Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections |
| Q37461413 | Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus |
| Q92304823 | Ceftobripole: Experience in staphylococcal bacteremia |
| Q36613912 | Cephalosporins for uncomplicated skin and skin structure infections in emerging community-acquired MRSA. |
| Q30369604 | Comparative study of the susceptibilities of major epidemic clones of methicillin-resistant Staphylococcus aureus to oxacillin and to the new broad-spectrum cephalosporin ceftobiprole. |
| Q37119259 | Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia |
| Q38797012 | Efficacy of Ceftaroline against Methicillin-Susceptible Staphylococcus aureus Exhibiting the Cefazolin High-Inoculum Effect in a Rat Model of Endocarditis. |
| Q38892614 | Efficacy of Telavancin Alone and in Combination with Ampicillin in a Rat Model of Enterococcus faecalis Endocarditis |
| Q36018587 | Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection model |
| Q35026567 | Emerging agents to combat complicated and resistant infections: focus on ceftobiprole |
| Q40600643 | Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model |
| Q41092910 | Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus |
| Q59335521 | Factors Contributing to the Evolution of -Mediated β-lactam Resistance in Staphylococci: Update and New Insights From Whole Genome Sequencing (WGS) |
| Q35964560 | Future trends in antimicrobial chemotherapy: expert opinion on the 43rd ICAAC. |
| Q42110143 | In Vivo Effects of Cefazolin, Daptomycin, and Nafcillin in Experimental Endocarditis with a Methicillin-Susceptible Staphylococcus aureus Strain Showing an Inoculum Effect against Cefazolin |
| Q35124610 | In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci |
| Q33559139 | In vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa |
| Q36932924 | In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models |
| Q35191417 | In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus |
| Q53905921 | Infective endocarditis. |
| Q33935282 | Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus |
| Q41863839 | Interaction of ceftobiprole with the low-affinity PBP 5 of Enterococcus faecium |
| Q37598693 | LB11058, a new cephalosporin with high penicillin-binding protein 2a affinity and activity in experimental endocarditis due to homogeneously methicillin-resistant Staphylococcus aureus |
| Q28235095 | Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey |
| Q43491015 | Methicillin/per-6-(4-methoxylbenzyl)-amino-6-deoxy-β-cyclodextrin 1:1 complex and its potentiation in vitro against methicillin-resistant Staphylococcus aureus |
| Q35005000 | Microtiter plate-based assay for inhibitors of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus. |
| Q40968003 | Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers |
| Q35056042 | Novel agents for the treatment of resistant Gram-positive infections |
| Q35073345 | Novel antibacterial agents for the treatment of serious Gram-positive infections |
| Q35547377 | PBP 2a mutations producing very-high-level resistance to beta-lactams |
| Q37274751 | Pharmacodynamic profiling of ceftobiprole for treatment of complicated skin and skin structure infections |
| Q35879080 | Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects |
| Q35715050 | Quality control guidelines for BAL9141 (Ro 63-9141), an investigational cephalosporin, when reference MIC and standardized disk diffusion susceptibility test methods are used |
| Q36422630 | Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. |
| Q40967997 | Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers |
| Q35111600 | Solving staphylococcal resistance to β-lactams |
| Q35806369 | Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus |
| Q44958662 | The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus |
| Q42747697 | Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates |
| Q37733667 | Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. |
Search more.